NASDAQ Equity Snapshot
KYTX Weekly Equity Report
Kyverna Therapeutics, Inc. Common Stock
What the company does
Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on developing cutting-edge immunotherapies for autoimmune diseases and other serious medical conditions. Utilizing its proprietary genetically engineered T-cell technology, Kyverna aims to enhance immune system functionality, offering specialized therapeutic solutions that promise better disease management outcomes. With a strategic emphasis on cellular therapies, the company is well-positioned to capitalize on the growing biopharmaceutical sector, presenting significant opportunities for institutional investors interested in cutting-edge treatments and the expanding immunotherapy landscape.
What the weekly tape is saying
KYTX closed the latest completed week at 8.05 USD. The 4-week return is -15.1% and the 12-week return is 1.4%. Trend Signal is inactive, Market Dynamics is -0.46. Setup signature: Risk-first tape with a 26/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 8.41 USD
- Vs Trend Line
- -4.2%
- Fair Value
- 7.91 USD
- Vs Fair Value
- 1.8%
- 52W High
- 13.67 USD
- 52W Low
- 2.52 USD
- Drawdown
- -41.1%
- Range Position
- 49.6%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 46
- 52W Active Breadth
- 88.5%
- Sector Scope
- US Healthcare
- Sector Rank
- 169 of 1038
- Sector Percentile
- 83.8%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
US Healthcare
- Tracked Peers
- 100
- 4W Rank
- - of 100
- Avg 1W
- 0.8%
- Avg 4W
- 3.5%
- Trend Breadth
- 33.0%
- Positive MD
- 41.0%
US Biotechnology
- Tracked Peers
- 100
- 4W Rank
- - of 100
- Avg 1W
- 4.9%
- Avg 4W
- 1.7%
- Trend Breadth
- 46.0%
- Positive RS
- 47.0%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- -0.46
- 4W MD Change
- -260.9%
- Relative Strength
- 0.20
- 4W RS Change
- -99.2%
- Expectation
- Negative
- Probability
- 37.43%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 3.1M
- 13W Average
- 4.5M
- 52W Average
- 4.2M
- Vs 13W
- 0.7x
- Vs 52W
- 0.7x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 8.0%
- 52W Volatility
- 13.1%
- Upside Weeks
- 27
- Downside Weeks
- 24
- Downside Breadth
- 46.2%
- Avg Gain / Loss
- 11.6% / -7.5%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- NASDAQ
- Country
- US
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
- Market Cap
- 518.0M
Opportunity signals
- Price is above Fair Value, showing premium demand versus the model.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Market Dynamics is negative, which weakens the current setup.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 8.05 USD | 7.8% | 8.41 USD | 7.91 USD | -0.46 | 0.20 | 3.1M | Off |
| 5 Jun 2026 | 7.47 USD | -12.3% | 8.37 USD | 7.91 USD | -0.12 | -4.10 | 4.4M | On |
| 29 May 2026 | 8.52 USD | -1.7% | 8.34 USD | 7.92 USD | 0.20 | 5.22 | 3.0M | On |
| 22 May 2026 | 8.67 USD | -8.6% | 8.29 USD | 7.91 USD | 0.21 | 11.46 | 4.6M | On |
| 15 May 2026 | 9.49 USD | 1.5% | 8.25 USD | 7.90 USD | 0.28 | 25.18 | 5.9M | On |
| 8 May 2026 | 9.35 USD | 5.4% | 8.15 USD | 7.89 USD | 0.24 | 24.93 | 3.1M | On |
| 1 May 2026 | 8.87 USD | -2.1% | 8.06 USD | 7.88 USD | 0.10 | 27.08 | 4.2M | On |
| 24 Apr 2026 | 9.06 USD | -8.8% | 7.95 USD | 7.87 USD | 0.06 | 33.92 | 14.2M | On |
| 17 Apr 2026 | 9.93 USD | 10.9% | 7.85 USD | 7.86 USD | -0.22 | 52.83 | 3.1M | On |
| 10 Apr 2026 | 8.95 USD | 0.9% | 7.71 USD | 7.84 USD | -0.52 | 49.45 | 3.5M | On |
| 2 Apr 2026 | 8.87 USD | 13.7% | 7.55 USD | 7.83 USD | -0.54 | 57.84 | 3.2M | On |
| 27 Mar 2026 | 7.80 USD | -1.8% | 7.38 USD | 7.82 USD | -0.58 | 47.41 | 3.0M | On |
| 20 Mar 2026 | 7.94 USD | -11.3% | 7.24 USD | 7.82 USD | -0.54 | 48.12 | 3.6M | On |
| 13 Mar 2026 | 8.95 USD | 10.5% | 7.11 USD | 7.82 USD | -0.55 | 66.70 | 3.3M | On |